Literature DB >> 18226896

Selective, high affinity A(2B) adenosine receptor antagonists: N-1 monosubstituted 8-(pyrazol-4-yl)xanthines.

Rao V Kalla1, Elfatih Elzein, Thao Perry, Xiaofen Li, Art Gimbel, Ming Yang, Dewan Zeng, Jeff Zablocki.   

Abstract

A series of N-1 monosubstituted 8-pyrazolyl xanthines have been synthesized and evaluated for their affinity for the adenosine receptors (AdoRs). We have discovered two compounds 18 (CVT-7124) and 28 (CVT-6694) that display good affinity for the A(2B) AdoR (K(i)=6 nM and 7 nM, respectively) and greater selectivity for the human A(1), A(2A), and A(3) AdoRs (>1000-, >830-, and >1500-fold; >850-, >700-, and >1280-fold, respectively). CVT-6694 has been shown to block the release of interleukin-6 and monocyte chemotactic protein-1 from bronchial smooth muscle cells (BSMC), a process believed to be promoted by activation of A(2B) AdoR.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18226896     DOI: 10.1016/j.bmcl.2008.01.008

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  4 in total

Review 1.  Xanthines as adenosine receptor antagonists.

Authors:  Christa E Müller; Kenneth A Jacobson
Journal:  Handb Exp Pharmacol       Date:  2011

2.  Ligand-, structure- and pharmacophore-based molecular fingerprints: a case study on adenosine A(1), A (2A), A (2B), and A (3) receptor antagonists.

Authors:  Francesco Sirci; Laura Goracci; David Rodríguez; Jacqueline van Muijlwijk-Koezen; Hugo Gutiérrez-de-Terán; Raimund Mannhold
Journal:  J Comput Aided Mol Des       Date:  2012-10-12       Impact factor: 3.686

3.  Latest QSAR study of adenosine Α₂Β receptor affinity of xanthines and deazaxanthines.

Authors:  Alfonso Pérez-Garrido; Virginia Rivero-Buceta; Gaspar Cano; Sanjay Kumar; Horacio Pérez-Sánchez; Marta Teijeira Bautista
Journal:  Mol Divers       Date:  2015-07-10       Impact factor: 2.943

4.  Progress in the discovery of selective, high affinity A(2B) adenosine receptor antagonists as clinical candidates.

Authors:  Rao V Kalla; Jeff Zablocki
Journal:  Purinergic Signal       Date:  2008-06-21       Impact factor: 3.765

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.